ABSTRACT
Systemic inflammation is characterized by the production of C-reactive protein (CRP) and the proinflammatory cytokines tumor necrosis factor-␣ (TNF␣) and interleukin 6 (IL-6). TNF␣ and IL-6 play a role in immune to brain communication by activating the central innate immune response to initiate a behavioral response known as sickness behavior. 1, 2 Sickness behavior refers to a coordinated set of behavioral changes that develop during the course of raised systemic inflammation. 3 These behaviors include increased anxiety, depressed mood, and apathy, and are adaptive protective mechanisms aimed at conserving energy and reducing further exposure to systemic inflammatory insults 4 (table e-1 on the Neurology ® Web site at www.neurology.org). In animal models of neurodegeneration, systemic inflammation results in a markedly increased central proinflammatory cytokine profile and the development of sickness behavior and neuronal cell loss. 5, 6 In Alzheimer disease (AD), we have shown that systemic inflammation, associated with raised serum proinflammatory cytokines, is associated with a marked increase in cognitive decline that is independent of acute cognitive deterioration associated with delirium. 7, 8 We hypothesized that in AD raised serum TNF␣ and IL-6 would also be associated with an exacerbation of neuropsychiatric symptoms characteristic of sickness behavior independent of the development of the behavioral symptoms of delirium.
METHODS Study design.
A total of 300 communitydwelling subjects with mild to severe dementia and their caregivers were recruited between November 2003 and May 2006 from clinical referrals to memory assessment services in Southampton, UK. Following consent procedures, all subjects fulfilling National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) 9 criteria for probable or possible AD were tested using the Alzheimer's Disease Assessment Scale Cognitive subscale (ADAS-Cog). 10 Immediately following cognitive assessment, a blood sample for assaying CRP and the proinflammatory cytokines TNF␣ and IL-6 was taken. At the end of the interview, the main caregiver was given a once-weekly checklist diary based on the Neuropsychiatric Inventory (NPI) 11 and the Confusion Assessment Method (CAM) 12 (see table e-1) in which to enter the presence of behavioral symptoms over the following 2 months and to alert the study coordinator if a delirium was suspected. The subjects' main caregiver was then formally interviewed 2 months later by a separate research nurse, blind to the initial cognitive assessment of the subject, using the NPI to determine (with cross-reference to the checklist) the presence of neuropsychiatric features and acute systemic inflammatory events (SIEs) over the preceding 2 months. An SIE was defined as a short-lived (less than 2 months duration) infection or trauma not directly involving the CNS with a minimum serum CRP level of 1 g/mL after the event. The NPI is a carer-based interview that assesses 10 behavioral disturbances in the subject. Based on animal and human clinical studies, [13] [14] [15] [16] [17] we identified 3 core symptoms from the NPI as being a priori compatible with the concept of sickness behavior (i.e., increased depression/ dysphoria, increased anxiety, and increased apathy). The main caregiver was revisited at 4 and 6 months with the NPI reassessed in an identical manner to that at 2 months.
All patients were cognitively reassessed 2, 4, and 6 months after baseline (within 2 days and independently of the NPI carer assessment) by the original patient assessor using the ADAS-Cog and the CAM to assess of the development of a delirium with additional blood sampling for inflammatory markers. The CAM operationalizes the core symptoms of delirium as defined by DSM-III-R 18 and has a high concordance with the DSM-IV diagnosis of delirium. 19 -21 Additional assessments using the CAM were carried out if a delirium was suspected by the main carer in between scheduled visits. Written informed consent was obtained from all patients (or guardians of patients) participating in the study.
Systemic inflammation assays.
Blood sera were immediately placed on ice and stored within 2 hours at Ϫ80°C. CRP was assayed using ELISA and had a detection limit of 1 g/mL. TNF␣ and IL-6 was assayed using sandwich immunoassay multispot cytokine assay (Meso Scale Discovery [MSD]). A protocol provided by MSD for custom assays was used with no major modifications. The lowest detectable limit was 1.1 pg/mL for TNF␣ and 0.7 pg/mL for IL-6.
Statistical analysis. Normality of continuous variables was determined by quantile-quantile plots of the residuals. Baseline age and ADAS-Cog were normally distributed. Serum CRP, TNF␣, and IL-6 levels were not normally distributed. Following previous guidelines, 22 low serum CRP was defined as Ͻ1.0 g/mL at all 4 timepoints; moderate/high levels were defined as above 1.0 g/mL at any timepoint. Serum TNF␣ and IL-6 levels were simplified by the use of quartile ranges, based on subject numbers found at baseline assessment. Low serum TNF␣ was defined as that found in the lowest quartile for TNF␣ (Ͻ2.4 pg/mL) at all 4 timepoints and high serum levels as above 2.4 pg/mL at any timepoint. Low serum IL-6 was defined as that found in the lowest quartile for IL-6 (Ͻ2.8 pg/mL) at all 4 timepoints and high serum levels as above 2.8 pg/mL at any timepoint. The average NPI score for each individual over the 6-month follow-up period was determined by taking the mean of the 3 NPI scores (product of the frequency and severity) at the 3 timepoints at 2, 4, and 6 months and was not normally distributed. Impairment of an individual NPI symptom was based on its presence (i.e., frequency of Ն1) at any time during the 6-month follow-up period. Allowing for a 10% dropout rate, 300 subjects gave 90% power to detect a significant difference (␣ ϭ 0.017) of 15% between the total NPI score in subjects in the lowest quartile compared to subjects in the top 3 quartiles. Relationships between variables was assessed using a mixture of Student t test, Fisher exact test, 2 , Mann Whitney U, and Spearman correlations. Data interaction was assessed using logistic regression analysis.
RESULTS
A total of 366 subjects were approached for inclusion. A total of 51 subjects or their carers declined participation; 15 subjects did not fulfill NINCDS-ADRDA criteria. The 51 nonparticipating subjects did not differ with respect to age (nonparticipants age 82. 2). A total of 25 subjects were clinically unresponsive at baseline with severe end-stage dementia, i.e., ADASCog scores greater than 60 points, and were excluded from further analysis due to the difficulty in assessing the development of a delirium over the follow-up period.
Baseline data. Of the 275 subjects, 161 (59%) fulfilled NINCDS-ADRDA criteria for probable AD and 114 (41%) possible AD. The mean age of the cohort at baseline was 82.7 (SD 7.4) years. A total of 99 (36%) subjects were men. At baseline, subjects had a mean ADAS-Cog score of 29.6 (SD 13.0) points. Blood sampling was obtained in 269/275 (98%) subjects at baseline. Median serum CRP was 2.5 (interquartile range [IQR] 0 -5.8) g/mL and was moderate/high (serum level Ն1 g/mL) in 186 (70%) subjects. Serum TNF␣ and IL-6 was detectable in all subjects (TNF␣ median 3.3 pg/mL [IQR 2.4 pg/mL-4.2 pg/mL]; IL-6 median 4.5 pg/mL [IQR 2.8 pg/mL-8.0 pg/mL]).
Low levels of all systemic inflammatory markers at baseline were associated with a younger age, but not gender. Low baseline levels of TNF␣, but not CRP or IL-6, were associated with lower ADAS-Cog scores at baseline (table 1) .
Six-month follow-up period. A total of 222 (81%) subjects had complete clinical and systemic inflammatory marker follow-up at 2, 4, and 6 months. Of the 53 subjects who did not complete the study, 15 subjects died before study completion and 38 subjects refused phlebotomy or further cognitive assessment at some point during the study. There was no significant difference between those subjects who completed the study in terms of age ( Subjects with delirium had a higher median NPI score over the 6-month follow-up period than those without identified delirium (delirium absent NPI score 6.7 [IQR 2.7-12.7] patients vs delirium present 11.0 patients, MWU p Ͻ 0.0001). The frequency of individual symptoms in subjects with or without delirium is shown in table 2 and figure e-1. All symptoms were numerically more frequent in subjects with delirium compared to those without delirium and this was Table 1 Baseline serum systemic inflammatory markers and demographics Systemic inflammatory markers. During the 6-month follow-up period, 27 subjects with low serum CRP levels at baseline had serum CRP levels that remained at less than 1.0 g/mL, 34 subjects with low serum TNF␣ levels at baseline had serum TNF␣ levels that remained at less than 2.4 pg/mL, and 29 subjects with low serum IL-6 levels at baseline had serum IL-6 levels that remained at less than 2.8 pg/mL.
Systemic inflammatory markers and delirium. Subjects with low CRP throughout the study were not less likely to experience an episode of delirium than subjects with high CRP (low CRP 3.7% vs high CRP 12.6%, 2 1.8, p ϭ 0.20). Likewise, subjects with low IL-6 throughout the study were not less likely to experience an episode of delirium than subjects with high IL-6 (low IL-6 3.4% vs high IL-6 12.4%, 2 2.0, p ϭ 0.15). There was a trend to suggest that subjects with low TNF␣ throughout the study were less likely to experience an episode of delirium than subjects with high TNF␣ (low TNF␣ 2.9% vs high TNF␣12.8%, 2 2.8, p ϭ 0.09).
Systemic inflammatory markers and neuropsychiatric
features. There was no statistical difference in the NPI score in subjects with low CRP levels throughout the 6-month follow-up period compared to subjects with high CRP levels (low CRP figure 1 . With the exception of disinhibition, all other symptoms were numerically more frequent in subjects with high levels of TNF␣ compared to those with low levels and this was statistically significant for the presence of agitation ( Subjects with low IL-6 levels throughout the 6-month follow-up period also had a lower NPI score over this same time period (low IL-6 4.3 [IQR 0.7-9.2] vs high IL-6 8.7 [IQR 3.7-13.8], MWU p ϭ 0.02). The frequency of individual symptoms in subjects with low compared to high levels of IL-6 is shown in figure 2 . All symptoms, with the exception of motor activity, were numerically more frequent in subjects with high levels of IL-6 compared to those with low levels, and this was statistically significant for the presence of hallucinations ( 2 6.0, p ϭ 0.015) and apathy ( 2 4.5, p ϭ 0.03) with a trend for delusions ( 2 2.6, p ϭ 0.1). The relationships between the presence of these symptoms and high IL-6 levels were largely unchanged following adjustment for The period prevalence of the 3 core features of sickness behavior for subjects experiencing specific SIEs is shown in table 3.
DISCUSSION
The history of cytokine-induced sickness behavior has been extensively reviewed elsewhere. 4, 23 We have argued that these symptoms are likely to be exaggerated and prolonged in subjects with AD due to prior microglial activation in AD 24 and to the effects of SIEs and chronic comorbid conditions associated with raised systemic inflammation, e.g., diabetes. 25 We have previously shown that raised serum TNF␣, but not CRP, is associated with increased cognitive decline in AD, independent of delirium 8 ; elsewhere there is evidence that raised serum TNF␣ and IL-6, but not CRP, is associated with cognitive impairment in diabetes. 26 Here we show that raised serum TNF␣ and IL-6, but not CRP, is associated with an approximately 2-fold increase of NPI scores and an increased frequency of neuropsychiatric symptoms characteristic of sickness behavior, independent of delirium. The lack of relationship between raised CRP as an indicator of systemic inflammation and behavioral symptoms may reflect findings in the elderly that CRP is neither a good predictor of systemic inflammation 27, 28 or involved in peripheral to brain communication of sickness behavior. Frequency distribution of neuropsychiatric features in subjects with Alzheimer disease over the 6-month follow-up period by low or high levels of interleukin-6 (IL-6) *p Յ 0.05, ** p Յ 0.01, adjusted for baseline age and gender. While every effort was made to identify episodes of delirium in this prospective study using wellvalidated tools, it is possible that some episodes of delirium may have been missed. However, the frequency of delirium found in this study is in keeping with other community studies of AD, 29, 30 and it is notable that the core features of sickness behavior symptoms (apathy, anxiety, and depression) were also common (occurring in around 80%) in those subjects without detectable delirium.
As hypothesized, we found that the 3 core symptoms of sickness behavior were more frequent in subjects with AD with a raised proinflammatory cytokine profile. There appears to be some variability in the effects of different inflammatory events on the development of sickness behavior but small numbers preclude any meaningful comparisons. However, high levels of TNF␣ and IL-6 were also associated with a general increased frequency of a wide range of symptoms which are not commonly identified as characteristic of sickness behavior (figure 2). These symptoms are common in AD, even in the absence of delirium, and may reflect an exaggerated cytokine response in the brain due to priming of the microglia and enhanced sensitivity to modest systemic inflammatory signals. 5, 25 The higher co-occurrence of sickness behavior in subjects with delirium raises the possibility that delirium may represent an extreme nonadaptive presentation of sickness behavior. Thus, there may be a continuum of behavioral changes: in healthy young individuals systemic inflammation inducing benign and transient changes in the CNS while similar systemic changes induce more severe symptoms in a population with dementia. Likewise, delirium may require a more severe systemic inflammation in healthy young individuals but only a mild event in individuals with dementia. 31 It is notable that the symptom profile shown by raised TNF␣ and IL-6 while both exhibiting apathy also differ. Thus, raised TNF␣ is associated with symptoms more characteristic of depressive symptomatology while raised IL-6 is more characteristic of a psychotic profile (figures 1 and 2 ) and is consistent with cluster analyses of the NPI in subjects with AD. 32 In addition, subjects with mild cognitive impairment show a NPI profile that is remarkably similar to that associated with sickness behavior, 33 suggesting that the early presentation of these symptoms might represent the neurochemical consequences of microglial activation and consequently explain their poor cognitive outcome. 34 
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